Only one in five patients seeking specialty care for resistant hypertension are taking all their prescribed medications, according to new research in the American Heart Association’s journal Hypertension.
“Another twenty percent are not taking any of their blood pressure medications,” said Peter Blankestijn, M.D., Ph.D., senior author of the study and professor of nephrology and hypertension at the University Medical Center Utrecht in the Netherlands. “People mistakenly thought to have resistant hypertension – which is high blood pressure despite taking three or more medications – end up seeing specialists and undergoing extra tests because we don’t understand why they are so difficult to treat.”
Statin side effects are the strongest predictor of failure to meet low-density lipoprotein (LDL) cholesterol targets, according to research published in the European Journal of Preventive Cardiology.Other predictors were statin non-adherence and use of weaker statins.
Heart disease patients taking PCSK9 inhibitors to achieve very low levels of cholesterol do not experience an increase in adverse events, including memory impairment or nervous system disorders, but may have an increased risk of cataracts, according to a study today in the Journal of the American College of Cardiology.
- Study reveals patients often struggle to manage their drug regime
Community pharmacists could be used more to support patients and carers
Some carers find the responsibility of their role stressful
The use of benzodiazepines and benzodiazepine-like drugs was associated with a 20 per cent increased risk of stroke among persons with Alzheimer’s disease, shows a recent study from the University of Eastern Finland. Benzodiazepines were associated with a similar risk of stroke as benzodiazepine-like drugs.
Regular use of aspirin by people living in Shanghai, China, was associated with decreased risk for developing pancreatic cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Data from the new study and meta-analysis of data from 18 other studies suggest that over the past two decades, as the general population’s use of aspirin has increased, the effect of aspirin in decreasing pancreatic cancer risk has become more pronounced.